Irish Startup Snags $120M for Heart Failure Implant
FIRE1 raised $120 million for its Norm system — a heart failure monitor implant that seeks to keep patients out of the hospital.
FDA Clears Withings’ New Blood Pressure Monitor That Allows Providers to Communicate Directly with Patients
This week, the FDA granted clearance to Withings’ BPM Pro 2 cellular blood pressure monitor. The device seeks to help providers scale remote patient monitoring for heart failure patients.
presented by
What Keeps Healthcare CIOs Up at Night: Balancing Technology Investments with Consumer Expectations
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
Bayer Looks to Expand Kerendia’s Label to Heart Failure After Phase 3 Win
Bayer reported a Phase 3 test of Kerendia in heart failure led to statistically significant reductions in cardiovascular death and hospitalizations. Detailed results will be presented during the European Society of Cardiology annual meeting in September.
Eko Health Gains FDA Clearance For Cardiology Algorithm That Can Detect Heart Failure in 15 Seconds
This week, Eko Health received FDA clearance for a new AI-powered tool that aids in the early detection of low ejection fraction, a key indicator of heart failure. The tool, which was developed in collaboration with Mayo Clinic, is embedded into Eko’s digital stethoscopes.
Novo Nordisk Expands Cardio Reach by Buying Heart Drugs Biotech Cardior
Novo Nordisk’s strategy to grow beyond metabolic diseases includes expanding into adjacent areas such as cardiovascular disease. Acquiring Cardior Pharmaceuticals adds a novel RNA-based therapy that is a potential heart failure treatment.
Geisinger Launches Heart Failure Monitoring Program Using Bodyport’s Smart Scale
Geisinger is launching a pilot program in partnership with virtual heart failure monitoring startup Bodyport. About 200 of the health system's heart failure patients will be using Bodyport’s cardiac scale at home — the scale uses sensors to measure a person’s metrics of heart function and body fluid status after they stand on it for about 20 seconds.
Using Data to Help Healthcare Practices Succeed
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
After FDA Miss in Diabetes, Lexicon Lands Long-Awaited Approval in Heart Failure
Lexicon Pharmaceuticals drug Inpefa is now FDA-approved for heart failure. Inpefa is third in its class, but the biotech says its pill can reach a specific subset of patients, enabling it to stand apart from rival medicines from AstraZeneca and partners Eli Lilly and Boehringer Ingelheim.
Intermountain Partners with Story Health to Better Manage Heart Failure Patients’ Care Plans
Intermountain Healthcare recently partnered with Story Health to help manage patients’ heart failure by increasing access to specialty care. Under the partnership, Intermountain clinicians are working with Story’s health coaches to help patients keep up with their treatment plans while they’re outside the walls of the doctor’s office.
Rocket Pharma stocks up on cardiac gene therapies with $53M Renovacor acquisition
Rocket Pharmaceuticals is acquiring Renovacor, a gene therapies developer whose lead program addresses a particular genetic mutation that leads to a type of heart failure. The all-stock deal gives Rocket the opportunity to expand its reach in genetically driven cardiac diseases.
Could AI and an Apple Watch ECG improve the prognosis for heart failure?
Early detection and treatment of heart failure can greatly improve an otherwise poor prognosis. Research from Mayo Clinic suggests artificial intelligence could be used to detect the condition even when no symptoms are present.
The Funding Model for Cancer Innovation is Broken — We Can Fix It
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
CEO of cardiology startup declares that its tech could potentially cure heart failure
Ceryx's device, Cysoni, is designed to pace the heart in rhythm with a person's respiration, so that the heart rate and breathing are synced. This is typically the case for a healthy person, but for someone with heart failure, that link becomes severed, CEO Stuart Plant said.
Imara’s two trial flops in blood disorders dim drug’s prospects in heart failure
The lead drug candidate of Imara failed two separate mid-stage clinical trials evaluating it in rare, inherited hemoglobin disorders. Imara had been planning to advance the small molecule to yet another Phase 2 study in heart failure, but in light of the twin trial failures, the biotech is now weighing “strategic options.”
WellSky’s in-home care pilot with Ohio academic medical center aims to reduce heart failure hospital readmissions
WellSky will pilot its ReD technology at The OSU Wexner Medical Center with the goal to help heart failure patients avoid hospital readmissions. The technology allows providers to assess the fluid level in patients' lungs accurately, deemed as a symptom of worsening heart condition.
To reduce heart attack rates, make CCTA the new standard of care
To improve heart attack prevention, there is an urgent unmet need to modernize our approach from late-stage symptom-driven care to direct disease-based care, a care paradigm that addresses heart attack risk in all patients across the entire continuum of heart disease severity.
Study: Rural hospitals that merged or were bought saw death rates drop
The mortality rates at rural hospitals for certain conditions, including heart attacks and stroke, decreased in the years following a merger or an acquisition compared with facilities that remained independent, a new study shows. This is a departure from research done on the effects of M&A on urban hospitals.